The Mazor Robotics Ltd – (MZOR) Downgraded by Wells Fargo & Co

The Mazor Robotics Ltd – (MZOR) Downgraded by Wells Fargo & Co

Several other equities analysts also recently commented on MZOR. Zacks Investment Research raised shares of Mazor Robotics Ltd – from a sell rating to a hold rating in a research note on Wednesday, January 11th. B. Riley reissued a neutral rating and issued a $25.00 price objective on shares of Mazor Robotics Ltd – in a research note on Friday, February 17th. Standpoint Research downgraded shares of Mazor Robotics Ltd – from a buy rating to a reduce rating and dropped their price objective for the company from $32.98 to $28.00 in a research note on Wednesday, April 19th. They noted that the move was a valuation call. Barclays PLC downgraded shares of Mazor Robotics Ltd – from an overweight rating to an equal weight rating and raised their price target for the company from $31.00 to $32.00 in a research note on Monday, April 24th. They noted that the move was a valuation call. Finally, First Analysis downgraded shares of Mazor Robotics Ltd – from an overweight rating to an equal weight rating and raised their price target for the company from $28.00 to $38.00 in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $31.50.

Wells Fargo & Co cut shares of Mazor Robotics Ltd – (NASDAQ:MZOR) from an outperform rating to a market perform rating in a report published on Thursday, May 11th.

Shares of Mazor Robotics Ltd – (NASDAQ MZOR) opened at 40.36 on Thursday. The stock’s market cap is $963.60 million. Mazor Robotics Ltd – has a 52-week low of $15.32 and a 52-week high of $45.64. The firm’s 50-day moving average price is $38.25 and its 200-day moving average price is $27.27. Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its quarterly earnings data on Wednesday, May 10th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. The company had revenue of $11.70 million during the quarter, compared to the consensus estimate of $11.49 million. Mazor Robotics Ltd – had a negative net margin of 55.57% and a negative return on equity of 40.07%. Mazor Robotics Ltd -‘s revenue for the quarter was up 82.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) EPS. On average, equities research analysts forecast that Mazor Robotics Ltd – will post ($0.72) earnings per share for the current fiscal year.

Shares of Mazor Robotics Ltd – (NASDAQ MZOR) opened at 40.36 on Thursday. The stock’s market cap is $963.60 million. Mazor Robotics Ltd – has a 52-week low of $15.32 and a 52-week high of $45.64. The firm’s 50-day moving average price is $38.25 and its 200-day moving average price is $27.27. Large investors have recently bought and sold shares of the company. Menora Mivtachim Holdings LTD. boosted its stake in Mazor Robotics Ltd – by 57.2% in the first quarter. Menora Mivtachim Holdings LTD. now owns 235,867 shares of the medical instruments supplier’s stock valued at $7,022,000 after buying an additional 85,867 shares during the period. Eagle Asset Management Inc. acquired a new position in shares of Mazor Robotics Ltd – during the first quarter worth about $225,000. Wells Fargo & Company MN boosted its position in shares of Mazor Robotics Ltd – by 46.3% in the first quarter. Wells Fargo & Company MN now owns 40,958 shares of the medical instruments supplier’s stock worth $1,220,000 after buying an additional 12,959 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Mazor Robotics Ltd – during the first quarter worth about $2,511,000. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Mazor Robotics Ltd – by 26.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 186,167 shares of the medical instruments supplier’s stock worth $5,542,000 after buying an additional 39,232 shares in the last quarter. Institutional investors own 24.72% of the company’s stock.

Mazor Robotics Ltd – Company Profile Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MZOR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Mazor Robotics Ltd – Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mazor Robotics Ltd – and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment